2 May 2014 - Sofosbuvir has been available since January 2014 for the treatment of patients with chronic hepatitis C infection. The Institute for Quality and Efficiency in Health Care (IQWiG) has completed an early benefit assessment pursuant to AMNOG (Pharmaceutical Market Restructuring Act), on whether sofosbuvir compared with the appropriate comparator therapy offers an additional benefit.

Although the dossier presented by the manufacturer provides evidence of an additional benefit for treatment-naïve patients and patients whose virus genotype 2. However, the extent can not be quantified. For patients with other virus types (genotypes 1 and 3-6) or together with HIV infection, appropriate data are missing from the dossier.

For more details, go to: https://www.iqwig.de/de/presse/pressemitteilungen/pressemitteilungen/sofosbuvir_fur_bestimmte_patienten_hinweis_auf_zusatznutzen.6099.html?&et_cid=4&et_lid=%208 [German]